JP2016514706A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514706A5
JP2016514706A5 JP2016503427A JP2016503427A JP2016514706A5 JP 2016514706 A5 JP2016514706 A5 JP 2016514706A5 JP 2016503427 A JP2016503427 A JP 2016503427A JP 2016503427 A JP2016503427 A JP 2016503427A JP 2016514706 A5 JP2016514706 A5 JP 2016514706A5
Authority
JP
Japan
Prior art keywords
testosterone
pharmaceutical composition
oral pharmaceutical
composition according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503427A
Other languages
English (en)
Japanese (ja)
Other versions
JP6307711B2 (ja
JP2016514706A (ja
Filing date
Publication date
Priority claimed from US13/843,403 external-priority patent/US20130225544A1/en
Application filed filed Critical
Priority claimed from PCT/US2014/030604 external-priority patent/WO2014145781A1/en
Publication of JP2016514706A publication Critical patent/JP2016514706A/ja
Publication of JP2016514706A5 publication Critical patent/JP2016514706A5/ja
Application granted granted Critical
Publication of JP6307711B2 publication Critical patent/JP6307711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503427A 2013-03-15 2014-03-17 経口送達用リポバランス長鎖テストステロンエステル Active JP6307711B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,403 2013-03-15
US13/843,403 US20130225544A1 (en) 2009-01-08 2013-03-15 Lipobalanced long chain testosterone esters for oral delivery
PCT/US2014/030604 WO2014145781A1 (en) 2013-03-15 2014-03-17 Lipobalanced long chain testosterone esters for oral delivery

Publications (3)

Publication Number Publication Date
JP2016514706A JP2016514706A (ja) 2016-05-23
JP2016514706A5 true JP2016514706A5 (enExample) 2017-04-27
JP6307711B2 JP6307711B2 (ja) 2018-04-11

Family

ID=51538095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503427A Active JP6307711B2 (ja) 2013-03-15 2014-03-17 経口送達用リポバランス長鎖テストステロンエステル

Country Status (16)

Country Link
US (2) US20160193227A1 (enExample)
EP (2) EP2968363B1 (enExample)
JP (1) JP6307711B2 (enExample)
KR (1) KR102238478B1 (enExample)
CN (1) CN105073118A (enExample)
AR (1) AR095538A1 (enExample)
AU (2) AU2014232475A1 (enExample)
BR (1) BR112015020849A2 (enExample)
CA (1) CA2942005C (enExample)
IL (1) IL240958B (enExample)
MX (1) MX2015010594A (enExample)
RU (1) RU2722592C2 (enExample)
TW (1) TW201521731A (enExample)
UY (1) UY35445A (enExample)
WO (1) WO2014145781A1 (enExample)
ZA (1) ZA201507700B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102618A1 (en) 2016-11-30 2018-06-07 Lipocine Inc. Oral testosterone tridecanoate therapy
EP3824296A4 (en) * 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
KR20250025748A (ko) * 2022-06-22 2025-02-24 리포신 인코포레이티드 (17-)-3-옥소안드로스트-4-엔-17-일 도데카노에이트 조성물 및 제조 및 사용 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL189235C (nl) * 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
GB1567515A (en) * 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
AU9177501A (en) * 2000-08-23 2002-03-04 Akzo Nobel Nv Novel testosterone ester formulation for human use
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US7138389B2 (en) 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
EP1871384A4 (en) * 2005-04-15 2012-01-25 Clarus Therapeutics Inc SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH
US8492369B2 (en) * 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CN101217963A (zh) * 2005-04-15 2008-07-09 克劳拉斯医疗有限公司 疏水性药物给药系统及含有疏水性药物的组合物
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions

Similar Documents

Publication Publication Date Title
CA2812372C (en) Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
IL314360A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
JP2014521660A5 (enExample)
JP2010525050A5 (enExample)
JP2015504924A5 (enExample)
JP2015520235A5 (enExample)
ES2983643T3 (es) Terapia oral con tridecanoato de testosterona
JP2016503030A5 (enExample)
CA3078723A1 (en) Oral testosterone undecanoate therapy
JP2016514706A5 (enExample)
RU2017110076A (ru) Фармацевтическая композиция и способы
AU2015326489A1 (en) Low dose oral pharmaceutical composition of isotretinoin
JP2016505050A5 (enExample)
RU2015128028A (ru) Длинноцепочечные липосбалансированные сложные эфиры тестостерона для пероральной доставки
WO2016016742A1 (en) Oral pharmaceutical composition of isotretinoin
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
WO2016161683A1 (zh) 一种他汀类药物组合物及胶囊制剂、其制备方法
JP2015507002A5 (enExample)
JP5969879B2 (ja) 医薬組成物
CN101897967A (zh) 一种治疗血脂异常的沙棘黄酮复方制剂
CN106413699B (zh) 外用药物组合物
WO2014150959A2 (en) Method and products for enhancing cellular uptake of drug and dietary supplements
JP2008231041A (ja) 末梢循環改善薬
WO2014064711A3 (en) Methods of administering raltegravir and raltegravir compositions